Comparing to conventional cancer therapies, i.e. surgery, radio, and chemotherapies, monoclonal antibody-based therapies are highly advantageous because of their high affinity and specificity natures. To further elaborate, it is desired because mAb is able to recognize a specific and well-defined target. Immune checkpoints on immune cells are one of the popular targets because it induced significant clinical outcomes when reacting with anti-PD-1/L1 or CTLA4 antibodies. Creative Biolabs is dedicated to providing a variety of immuno-oncology programs to develop novel therapeutic antibodies with a goal to treat cancers. This program aims to develop the therapeutic monoclonal antibody against KLRG1 - an immune checkpoint expressed on NK cells.
Learn more: Next-IO™ Anti-KLRG1 Monoclonal Antibody Program